29.83
0.46 (1.57%)
| Previous Close | 29.37 |
| Open | 29.60 |
| Volume | 522,719 |
| Avg. Volume (3M) | 707,711 |
| Market Cap | 1,397,344,640 |
| Price / Earnings (TTM) | 64.85 |
| Price / Sales | 1.12 |
| Price / Book | 1.02 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | 1.13% |
| Operating Margin (TTM) | 4.49% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 18.60% |
| Quarterly Earnings Growth (YOY) | 55.40% |
| Total Debt/Equity (MRQ) | 30.77% |
| Current Ratio (MRQ) | 1.37 |
| Operating Cash Flow (TTM) | 187.72 M |
| Levered Free Cash Flow (TTM) | 146.87 M |
| Return on Assets (TTM) | 0.16% |
| Return on Equity (TTM) | 1.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | Omnicell, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 101.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Benchmark, 34.09%) | Buy |
| Median | 36.50 (22.36%) | |
| Low | 34.00 (B of A Securities, 13.98%) | Hold |
| Average | 36.75 (23.20%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 28.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 23 May 2025 | 34.00 (13.98%) | Hold | 28.23 |
| Wells Fargo | 23 May 2025 | 37.00 (24.04%) | Buy | 28.23 |
| 14 May 2025 | 35.00 (17.33%) | Buy | 28.73 | |
| Benchmark | 07 May 2025 | 40.00 (34.09%) | Buy | 24.63 |
| JP Morgan | 20 Mar 2025 | 36.00 (20.68%) | Hold | 34.88 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 22 May 2025 | Announcement | Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program |
| 14 May 2025 | Announcement | Omnicell Opens New Innovation Lab in Austin, Texas |
| 14 May 2025 | Announcement | Omnicell Announces New Products for Perioperative and Clinic Settings |
| 06 May 2025 | Announcement | Omnicell Announces First Quarter 2025 Results |
| 14 Apr 2025 | Announcement | Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025 |
| 24 Mar 2025 | Announcement | Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |